Mymetics is focused on several pathways to develop prophylactic vaccines and immunotherapies with virosomes:
- The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer and generating mucosal and serum antibodies
- Improve the working of the immune system through generation of specific CD4+ and CD8+ T cells, especially needed for oncology immunotherapies
- The development of a thermostable and cold chain virosome vaccine formulations that can be administered through intra-nasal, sub lingual or oral routes.
Using these pathways, our pipeline comprises vaccine candidates at various stages of clinical development under our own development or in collaboration with partners.
Note: Please read recent SEC filings of the Company. We are investigating strategic alternatives, including a wind down of the operations. There can be no certainty or conclusion on the future of the Company.
